Literature DB >> 32234499

Hsa_circ_0011290 regulates proliferation, apoptosis and glycolytic phenotype in papillary thyroid cancer via miR-1252/ FSTL1 signal pathway.

Zhigang Hu1, Pengxin Zhao1, Kaili Zhang1, Leilei Zang1, Haiying Liao1, Weiyuan Ma2.   

Abstract

OBJECTIVE: Despite of previous report regarding the aberrant overexpression of hsa_circ_0011290 in thyroid cancer, the regulatory mechanism and mechanistic involvements of which were still elusive currently in papillary thyroid cancer (PTC). Here we set out to characterize expression status and functional contributions of hsa_circ_0011290 in this disease especially through mode-of-action of sponging RNA.
METHODS: Relative expression of hsa_circ_0011290, microRNA (miR)-1252 and FSTL1 was quantified by real-time polymerase chain reaction. Glucose metabolism was determined by examination of glucose uptake, lactate production and ATP contents. The regulatory effects of miR-1252 on both hsa_circ_0011290 and Follistatin Like 1 (FSTL1) were interrogated by luciferase reporter assay. Direct binding between miR-1252 with hsa_circ_0011290 and FSTL1 transcripts were analyzed by RNA pulldown assay. Protein levels of FSTL1 was examined by Western blots.
RESULTS: Aberrant over-expression of hsa_circ_0011290 was associated with advanced stage and unfavorable prognosis of PTC. Knockdown of hsa_circ_0011290 greatly inhibited cell viability, proliferation and stimulated cell apoptosis in PTC cells. Meanwhile, glucose metabolism was significantly switched with decreased glucose uptake and lactate production, and increased ATP contents. We identified miR-1252 as target miR of hsa_circ_0011290, and miR-1252 evidently inhibited expressions of both luciferase reporter and endogenous hsa_circ_0011290, and miR-1252 was negatively regulated by hsa_circ_0011290 vice versa. We further suggested that FSTL1 as direct target of miR-1252, and provided direct evidences in support of binding between miR-1252 with both hsa_circ_0011290 and FSTL1. Through sponging miR-1252, hsa_circ_0011290 was capable of positively modulate FSTL1 expression. Notably, inhibition of miR-1252 completely reversed phenotypic effects of hsa_circ_0011290 knockdown including cell viability, proliferation, apoptosis and glucose metabolisms.
CONCLUSION: Our study uncovered the oncogenic contributions of hsa_circ_0011290-miR-1252-FSTL1 in PTCs.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FSTL1; Thyroid cancer; hsa_circ_0011290; miR-1252

Year:  2020        PMID: 32234499     DOI: 10.1016/j.abb.2020.108353

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  6 in total

1.  Inhibition of microRNA-143-3p Attenuates Cerebral Ischemia/Reperfusion Injury by Targeting FSTL1.

Authors:  Shunda Wang; Zhenguo Liu
Journal:  Neuromolecular Med       Date:  2021-03-11       Impact factor: 3.843

2.  Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.

Authors:  Chenyu Ding; Xuehan Yi; Xiangrong Chen; Zanyi Wu; Honghai You; Xiaoyong Chen; Gaoqi Zhang; Yong Sun; Xingyao Bu; Xiyue Wu; Zhangya Lin; Jianjun Gu; Yuanxiang Lin; Dezhi Kang
Journal:  J Exp Clin Cancer Res       Date:  2021-05-11

3.  MiRNA-34c-5p protects against cerebral ischemia/reperfusion injury: involvement of anti-apoptotic and anti-inflammatory activities.

Authors:  Yaoran Tu; Yong Hu
Journal:  Metab Brain Dis       Date:  2021-04-12       Impact factor: 3.655

Review 4.  Function and Clinical Significance of Circular RNAs in Thyroid Cancer.

Authors:  Xuelin Yao; Qiu Zhang
Journal:  Front Mol Biosci       Date:  2022-07-22

Review 5.  A Review and In Silico Analysis of Tissue and Exosomal Circular RNAs: Opportunities and Challenges in Thyroid Cancer.

Authors:  Eman A Toraih; Mohammad H Hussein; Manal S Fawzy; Emad Kandil
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

Review 6.  CircRNA: A novel potential strategy to treat thyroid cancer (Review).

Authors:  Guomao Zhu; Xingyu Chang; Yuchen Kang; Xinzhu Zhao; Xulei Tang; Chengxu Ma; Songbo Fu
Journal:  Int J Mol Med       Date:  2021-09-16       Impact factor: 4.101

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.